U.S. regulations are too cautious. Europe has adopted a more sensible approach.

AEI's Scott Gottlieb argues that the focus of legislation should not be on creating employment benefits specifically targeted to H1N1, but instead on ways to mitigate risks in future pandemics by providing Americans with early vaccinations.

The development of antivirals for pandemic flu provides important insights into the pharmaceutical industry's ability to advance public health.

It is shocking that no leader has tried to ensure that Congress can function through a catastrophe, whether caused by terrorism or epidemic.

The plans Bush released last weekaboutpreparing for an outbreak of avian flu arecommendable; the challenge will be putting them into effect.

Bowman considers new polls on the FDA, jury duty, consumer confidence, and Michael Moore.

What are the odds of another pandemic--this time, bird flu--happening?

Ernst R. Berndt and Anjli C. Warner discuss their new book, U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies.